Anti-EFGRv3 monoclonal antibody
US8506963B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 22, 2009 |
| Grant date | Aug 13, 2013 |
| Priority date | — |
| Expiry date | Sep 22, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.